Therapeutic efficacy of intravenously administered transferrin-conjugated dendriplexes on prostate carcinomas

Majed Mansour Madi Al Robaian, Ker Yi Chiam, David Blatchford, Christine Dufès

Research output: Contribution to journalArticle

  • 15 Citations

Abstract

Aim: Improved treatments for prostate cancer are critically needed in order to overcome metastasis and lethal recurrence. Intravenously administered gene therapy would be an attractive anticancer treatment strategy; however, the lack of suitable carrier systems able to selectively deliver therapeutic genes to tumors has so far limited this investigation. Given that transferrin receptors are overexpressed on prostate cancer cells, the purpose of this study is to determine whether transferrin-conjugated dendriplexes encoding TNF-α, TNF-related apoptosis-inducing ligand and IL-12 would suppress the growth of prostate cancer cell lines in vitro and in vivo. Materials & methods: Transferrin-conjugated dendriplexes encoding TNF-α, TNF-related apoptosis-inducing ligand and IL-12 were intravenously administered to mice bearing subcutaneous PC-3 and DU145 tumors. Results: The administration of the transferrin-conjugated generation 3 diaminobutyric polypropylenimine dendriplex encoding TNF-α resulted in tumor suppression for 60% of PC-3 and 50% of DU145 prostate tumors. Conclusion: These dendriplexes hold great potential as a novel approach for prostate cancer therapy.
LanguageEnglish
Pages421-434
Number of pages4
JournalNanomedicine
Volume9
Issue number4
DOIs
StatePublished - 2014

Fingerprint

Transferrin
tumor
Tumors
Prostate
cancer
Prostatic Neoplasms
TNF-Related Apoptosis-Inducing Ligand
Carcinoma
Tumor Necrosis Factor-alpha
apoptosis
Cell death
Interleukin-12
PC
ligand
Neoplasms
Bearings (structural)
Ligands
Cells
gene therapy
Gene therapy

Keywords

  • prostate cancer cells
  • carcinomas

Cite this

Al Robaian, Majed Mansour Madi ; Chiam, Ker Yi ; Blatchford, David ; Dufès, Christine. / Therapeutic efficacy of intravenously administered transferrin-conjugated dendriplexes on prostate carcinomas. In: Nanomedicine. 2014 ; Vol. 9, No. 4. pp. 421-434
@article{0d465820ba0d46d59f028b05e0fe242d,
title = "Therapeutic efficacy of intravenously administered transferrin-conjugated dendriplexes on prostate carcinomas",
abstract = "Aim: Improved treatments for prostate cancer are critically needed in order to overcome metastasis and lethal recurrence. Intravenously administered gene therapy would be an attractive anticancer treatment strategy; however, the lack of suitable carrier systems able to selectively deliver therapeutic genes to tumors has so far limited this investigation. Given that transferrin receptors are overexpressed on prostate cancer cells, the purpose of this study is to determine whether transferrin-conjugated dendriplexes encoding TNF-α, TNF-related apoptosis-inducing ligand and IL-12 would suppress the growth of prostate cancer cell lines in vitro and in vivo. Materials & methods: Transferrin-conjugated dendriplexes encoding TNF-α, TNF-related apoptosis-inducing ligand and IL-12 were intravenously administered to mice bearing subcutaneous PC-3 and DU145 tumors. Results: The administration of the transferrin-conjugated generation 3 diaminobutyric polypropylenimine dendriplex encoding TNF-α resulted in tumor suppression for 60{\%} of PC-3 and 50{\%} of DU145 prostate tumors. Conclusion: These dendriplexes hold great potential as a novel approach for prostate cancer therapy.",
keywords = "prostate cancer cells, carcinomas",
author = "{Al Robaian}, {Majed Mansour Madi} and Chiam, {Ker Yi} and David Blatchford and Christine Duf{\`e}s",
year = "2014",
doi = "10.2217/NNM.13.25",
language = "English",
volume = "9",
pages = "421--434",
journal = "Nanomedicine",
issn = "1743-5889",
number = "4",

}

Therapeutic efficacy of intravenously administered transferrin-conjugated dendriplexes on prostate carcinomas. / Al Robaian, Majed Mansour Madi; Chiam, Ker Yi; Blatchford, David; Dufès, Christine.

In: Nanomedicine, Vol. 9, No. 4, 2014, p. 421-434.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Therapeutic efficacy of intravenously administered transferrin-conjugated dendriplexes on prostate carcinomas

AU - Al Robaian,Majed Mansour Madi

AU - Chiam,Ker Yi

AU - Blatchford,David

AU - Dufès,Christine

PY - 2014

Y1 - 2014

N2 - Aim: Improved treatments for prostate cancer are critically needed in order to overcome metastasis and lethal recurrence. Intravenously administered gene therapy would be an attractive anticancer treatment strategy; however, the lack of suitable carrier systems able to selectively deliver therapeutic genes to tumors has so far limited this investigation. Given that transferrin receptors are overexpressed on prostate cancer cells, the purpose of this study is to determine whether transferrin-conjugated dendriplexes encoding TNF-α, TNF-related apoptosis-inducing ligand and IL-12 would suppress the growth of prostate cancer cell lines in vitro and in vivo. Materials & methods: Transferrin-conjugated dendriplexes encoding TNF-α, TNF-related apoptosis-inducing ligand and IL-12 were intravenously administered to mice bearing subcutaneous PC-3 and DU145 tumors. Results: The administration of the transferrin-conjugated generation 3 diaminobutyric polypropylenimine dendriplex encoding TNF-α resulted in tumor suppression for 60% of PC-3 and 50% of DU145 prostate tumors. Conclusion: These dendriplexes hold great potential as a novel approach for prostate cancer therapy.

AB - Aim: Improved treatments for prostate cancer are critically needed in order to overcome metastasis and lethal recurrence. Intravenously administered gene therapy would be an attractive anticancer treatment strategy; however, the lack of suitable carrier systems able to selectively deliver therapeutic genes to tumors has so far limited this investigation. Given that transferrin receptors are overexpressed on prostate cancer cells, the purpose of this study is to determine whether transferrin-conjugated dendriplexes encoding TNF-α, TNF-related apoptosis-inducing ligand and IL-12 would suppress the growth of prostate cancer cell lines in vitro and in vivo. Materials & methods: Transferrin-conjugated dendriplexes encoding TNF-α, TNF-related apoptosis-inducing ligand and IL-12 were intravenously administered to mice bearing subcutaneous PC-3 and DU145 tumors. Results: The administration of the transferrin-conjugated generation 3 diaminobutyric polypropylenimine dendriplex encoding TNF-α resulted in tumor suppression for 60% of PC-3 and 50% of DU145 prostate tumors. Conclusion: These dendriplexes hold great potential as a novel approach for prostate cancer therapy.

KW - prostate cancer cells

KW - carcinomas

UR - http://www.futuremedicine.com/loi/nnm

U2 - 10.2217/NNM.13.25

DO - 10.2217/NNM.13.25

M3 - Article

VL - 9

SP - 421

EP - 434

JO - Nanomedicine

T2 - Nanomedicine

JF - Nanomedicine

SN - 1743-5889

IS - 4

ER -